Form 4: Pulmonx GC Sells Shares for Tax Obligations

Pulmonx General Counsel David Aaron Lehman sold 9,769 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• David Aaron Lehman, General Counsel of Pulmonx Corp, reported the sale of 9,769 shares of common stock.
• The sales occurred on September 2, 2025, at a price of $1.6 per share.
• These transactions were executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) granted on March 1, 2022, March 1, 2023, March 1, 2024, and March 3, 2025.
• The transactions were made pursuant to a Rule 10b5-1 pre-arranged trading plan.
• Following these transactions, Lehman's direct beneficial ownership decreased to 263,270 shares.

Sentiment

Score: 6

Explanation: The transaction is a routine, non-discretionary sale for tax purposes related to RSU vesting, which is a neutral event. It indicates the executive is realizing value from past compensation, but also reduces their direct stake. The future transaction date and 10b5-1 plan confirm its pre-planned, non-discretionary nature, mitigating any negative signal.

Positives

• The sales are non-discretionary, driven by tax obligations from RSU vesting, indicating the executive is realizing value from previously granted equity compensation.
• The transaction was executed under a Rule 10b5-1 plan, which suggests it was pre-scheduled and not based on new, material non-public information.

Negatives

• The sale of shares by an insider, even for tax purposes, reduces their direct ownership stake in the company.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general implication of insider selling, which is mitigated by the stated reason (tax withholding) and the 10b5-1 plan.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This Form 4 filing reports a routine insider transaction for tax purposes, which is common across all industries when executives' equity awards vest. It does not provide specific insights into broader industry trends or competitive landscape for Pulmonx Corp.

Comparison to Industry Standards

• The reported transaction is a standard practice for executives to cover tax obligations upon the vesting of equity awards. Such sales are common across publicly traded companies and do not typically reflect a discretionary view on the company's future performance.
• For example, executives at companies like Medtronic or Intuitive Surgical also routinely sell shares for tax withholding upon RSU vesting, which is a non-discretionary event often executed under Rule 10b5-1 plans.

Stakeholder Impact

• Shareholders: A slight reduction in insider ownership, but for a non-discretionary reason, so minimal negative signal.
• Management: The General Counsel is realizing value from equity compensation.

Next Steps

• No specific future actions or milestones are mentioned in this Form 4 filing beyond the completion of the reported transaction.

Key Dates

Recommendation

The reported transaction is a routine, non-discretionary sale by an insider to cover tax obligations upon RSU vesting, executed under a Rule 10b5-1 plan. This type of transaction is common and generally does not signal a change in the executive's confidence in the company's future prospects. Therefore, it provides no new fundamental information to warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Pulmonx, LUNG, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, David Aaron Lehman, General Counsel, 10b5-1 Plan